Obalon therapeutics inc (OBLN)
Income statement / Quarterly
Dec'19Sep'19Jun'19Mar'19Dec'18Sep'18Jun'18Mar'18Dec'17Sep'17Jun'17Mar'17Dec'16Sep'16Jun'16Mar'16Sep'15
Revenue:
Revenue

781

333

386

1,800

2,101

3,000

2,700

1,300

-

2,787

1,963

-

-

-

-

-

-

Cost of revenue

-

412

679

1,232

-

1,418

1,732

769

-

1,314

990

-

-

-

-

-

-

Revenue

-

-

-

-

-

-

-

-

-

-

-

1,472

0

0

0

0

-

Revenue, related party

-

-

-

-

-

-

-

-

-

-

-

-

772

773

779

1,069

1,093

Revenues

-

-

-

-

-

-

-

-

-

-

-

-

772

773

779

1,069

1,093

Cost of revenue

-

-

-

-

-

-

-

-

-

-

-

823

871

644

672

622

644

Gross profit

160

-79

-293

543

532

1,569

1,000

577

1,990

1,473

973

649

-99

129

107

447

449

Operating expenses:
Research and development

1,492

1,174

1,788

2,439

2,338

2,368

3,352

2,639

2,689

2,798

2,760

2,400

2,605

2,169

2,586

2,512

3,201

Selling, general and administrative

3,643

2,489

4,332

6,204

6,854

5,836

7,250

10,006

9,223

7,813

5,853

5,940

4,830

2,412

1,596

1,379

618

Total operating expenses

5,135

3,663

6,120

8,643

9,192

8,204

10,602

12,645

11,912

10,611

8,613

8,340

7,435

4,581

4,182

3,891

3,819

Loss from operations

-4,975

-3,742

-6,413

-8,100

-8,660

-6,635

-9,602

-12,068

-9,922

-9,138

-7,640

-7,691

-7,534

-4,452

-4,075

-3,444

-3,370

Interest expense, net

63

37

-295

-190

-62

-70

-57

-37

-25

-21

-35

-54

-52

-135

-143

-147

-142

Loss from change in fair value of warrant liability

-

-

-

-

-

-

-

-

-

-

-

-

-84

669

-96

-23

42

Other expense

-1

-1

-59

0

-34

-40

-94

-21

-173

-11

-55

0

7

-4

-9

-13

-8

Net Income (Loss) Attributable to Parent

-4,913

-3,706

-6,767

-8,290

-8,756

-6,745

-9,753

-12,126

-10,120

-9,170

-7,730

-7,745

-7,495

-5,260

-4,131

-3,581

-3,562

Other Comprehensive Income (Loss), Net of Tax

0

0

0

0

2

-3

0

6

-1

15

0

-18

-6

1

6

-2

-2

Net loss and comprehensive loss

-4,913

-3,706

-6,767

-8,290

-8,754

-6,748

-9,753

-12,120

-10,121

-9,155

-7,730

-7,763

-7,501

-5,259

-4,125

-3,583

-3,564

Net loss per share, basic and diluted (in dollars per share)

-3.81

-0.61

-0.25

-0.36

-14.89

-3.47

-0.57

-0.71

-0.60

-0.55

-0.46

-0.47

13.98

-5.46

-7.15

-6.22

-6.21

Weighted-average common shares outstanding, basic and diluted (in shares)

-37,224

6,061

26,877

23,112

-28,357

1,945

17,039

16,986

16,921

16,747

16,637

16,562

14,770

963

577

575

574